Business Wire

VA-DXC-TECHNOLOGY

21.5.2020 15:02:13 CEST | Business Wire | Press release

Share
DXC Introduces Corporate Incident Response Application to Help Businesses Proactively Reduce Risk

DXC Technology (NYSE: DXC) today introduced its Corporate Incident Response (CIR) application for ServiceNow to enable organizations like Banco Santander, one of the largest retail and commercial banks in the world, and the Nordex Group, one of the world’s largest wind turbine manufacturers, to quickly and proactively identify, address and manage important non-IT corporate incidents, such as those related to facilities, physical security, and environment, health and safety. The application, built on the ServiceNow platform, allows businesses to reduce their risk profiles and overcome situations before they evolve into companywide crises.

The CIR application provides an end-to-end workflow management solution to manage, track and respond to non-IT-related issues in an efficient, standardized manner.

“In today’s world, business disruptions are inevitable. While operational resilience has been around for years, a change in mindset is required in order to prevent, respond to, recover from, and most importantly, learn from and adapt after crises occur,” said Dan Stoks, vice president, Global ServiceNow Practice, DXC Technology. “The Corporate Incident Response application can work with ServiceNow’s integrated risk management and other workflows to enable organizations to securely manage crisis response workflows and risks to the business.”

Key features of the solution:

  • Situation rooms — provide a central point of collaboration for dispersed organizations to orchestrate response teams and plans and monitor and evaluate the overall picture.
  • App notifications — provide the ability to send companywide notifications, such as alerts, push notifications, email and SMS to predefined groups as well as external partners and customers.
  • 360-degree view — provides the management team with a 360-degree view of where the organization stands on corporate-related incidents, so they can make fact-based decisions that reduce their overall risk profile.

Banco Santander Streamlines Crisis Management Systems with DXC CIR Application

Banco Santander wanted a single platform to manage its global facility and security processes and replace its previous system with a new, digitized platform. Using the DXC CIR application with ServiceNow, Santander streamlined its processes with better-performing facility, security and crisis management systems and improved user experiences for its managers and end users. It also benefited from better insights and greater transparency in its global facility and security services.

“The consolidation of existing and new facility management capabilities to a new platform was a crucial part of our business transformation journey,” said Galo Gilarranz Vicente, Real Estate, General Services and Security, Banco Santander. “DXC’s CIR application has allowed us to reduce costs by rationalizing the global application landscape, standardize our processes and increase employee efficiency with automation.”

The Nordex Group Improves Worker Safety with DXC’s Health, Safety and Environmental Management Business Expertise

The Nordex Group tapped the DXC Health, Safety and Environment Suite (HSE) for ServiceNow, which is part of DXC’s CIR portfolio, to create a safety-driven culture throughout its global operations. With the DXC suite, the Nordex Group experienced a more streamlined process to reduce worker hazards and prevent incidents before they occur.

“Nordex is committed to worker safety, implementing proper processes to prevent and quickly respond to work-related incidents,” said Philipp Marten, program manager, Business Systems, Nordex Group. “With DXC’s HSE solution, we were able to reduce the complexity of our system, streamline reporting and create a safer work environment throughout our global operations.”

DXC is offering this application for free for 120 days to complement and enhance the capabilities of ServiceNow Emergency Response Management applications.

“Operational risk management is a crucial part of how ServiceNow enables resilience for our customers for both IT and non-IT operations,” said David Parsons, senior vice president, Global Alliances and Channel Ecosystem, ServiceNow. “Corporate Incident Response from DXC Technology exemplifies the innovative applications that extend the value of the Now Platform and our Risk and Business Continuity portfolio to serve critical and emerging use cases for joint customers enterprise-wide.”

To learn more and download the CIR for ServiceNow application, click here .

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye